Search Results "#TargetedTherapy"

Blogs

arrow_forward View More Results
MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?
Posted by Surbhi on July 10 2026 at 05:32 PM   public
MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringW...
Oncogene Inhibitor Market: How Are KRAS Inhibitors Unlocking the Once 'Undruggable' Target in Precision Oncology?
Posted by Surbhi on June 29 2026 at 05:01 PM   public
KRAS inhibitor breakthroughs — the targeted therapies addressing the most frequently mutated oncogene in human cancers (present in approximately 25% of all tumors) that was considered pharmacolog...
Oculodentodigital Syndrome Market: How Is Connexin 43 Targeted Therapy Emerging from the Gap Junction Biology Revolution?
Posted by Surbhi on June 29 2026 at 04:28 PM   public
Connexin 43 targeted therapy for oculodentodigital dysplasia — the precision medicine approach addressing the underlying GJA1 mutation disrupting gap junction intercellular communication, represe...
arrow_forward